- Home
- GPCR vs ELVN Comparison
GPCR vs ELVN Comparison
Compare GPCR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPCR | ELVN |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GPCR | ELVN |
|---|---|---|
| Price | $32.63 | $21.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $69.57 | $41.20 |
| AVG Volume (30 Days) | ★ 1.2M | 506.7K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.22 | $13.30 |
| 52 Week High | $40.29 | $25.96 |
Technical Indicators
Market Signals| Indicator | GPCR | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 53.34 |
| Support Level | $33.55 | $19.58 |
| Resistance Level | $36.09 | $22.14 |
| Average True Range (ATR) | 2.46 | 1.31 |
| MACD | -0.65 | -0.04 |
| Stochastic Oscillator | 19.36 | 52.07 |
Price Performance
Historical ComparisonAbout GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.